[go: up one dir, main page]

NO20022325L - Anvendelse av 9-substituerte hypoxantinderivater for å stimulere regenerering av nervevev - Google Patents

Anvendelse av 9-substituerte hypoxantinderivater for å stimulere regenerering av nervevev

Info

Publication number
NO20022325L
NO20022325L NO20022325A NO20022325A NO20022325L NO 20022325 L NO20022325 L NO 20022325L NO 20022325 A NO20022325 A NO 20022325A NO 20022325 A NO20022325 A NO 20022325A NO 20022325 L NO20022325 L NO 20022325L
Authority
NO
Norway
Prior art keywords
substituted hypoxanthine
compound
nerve tissue
regeneration
mammalian
Prior art date
Application number
NO20022325A
Other languages
English (en)
Other versions
NO20022325D0 (no
Inventor
Glasky Alvin
Original Assignee
Neotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neotherapeutics Inc filed Critical Neotherapeutics Inc
Publication of NO20022325L publication Critical patent/NO20022325L/no
Publication of NO20022325D0 publication Critical patent/NO20022325D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det beskrives en fremgangsmåte ved stimulering av regenera- sjon eller overlevelse av en motorisk neuron av et pattedyr eller en sensorisk neuron av et pattedyr, omfattende å administrere til et pattedyr en virksom mengde av en for- bindelse som er et 9-substituert hypoxantinderivat som er bundet via et bindeledd til en p-aminobenzosyreenhet, eller av et salt eller en prodrogeester av en slik forbindelse. Fortrinnsvis er forbindelsen N-4-karboksyfenyl-3-(6-okso- hydropurin-9-yl)propanamid. Det beskrives også farmasøy- tiske sammensetninger som er formulert for å stimulere en regenerasjon av en motorisk neuron av et pattedyr, omfat- tende det 9-substituerte hypoxantinderivat og en farmasøy- tisk akseptabel bærer.
NO20022325A 1999-11-16 2002-05-15 Anvendelse av 9-substituerte hypoxantinderivater for å stimulere regenerering av nervevev NO20022325D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/442,151 US6288069B1 (en) 1999-11-16 1999-11-16 Use of 9-substituted hypoxanthine derivatives to stimulate regeneration of nervous tissue
PCT/US2000/041645 WO2001036419A1 (en) 1999-11-16 2000-10-27 Use of 9-substituted hypoxanthine derivatives to stimulate regeneration of nervous tissue

Publications (2)

Publication Number Publication Date
NO20022325L true NO20022325L (no) 2002-05-15
NO20022325D0 NO20022325D0 (no) 2002-05-15

Family

ID=23755734

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022325A NO20022325D0 (no) 1999-11-16 2002-05-15 Anvendelse av 9-substituerte hypoxantinderivater for å stimulere regenerering av nervevev

Country Status (12)

Country Link
US (1) US6288069B1 (no)
EP (1) EP1230242A1 (no)
JP (1) JP2003517469A (no)
KR (1) KR20020050283A (no)
AU (1) AU3637901A (no)
BR (1) BR0015574A (no)
CA (1) CA2387809A1 (no)
EA (1) EA200200572A1 (no)
IL (1) IL149561A0 (no)
MX (1) MXPA02004935A (no)
NO (1) NO20022325D0 (no)
WO (1) WO2001036419A1 (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020091133A1 (en) * 2000-12-12 2002-07-11 Eve M. Taylor Use of 9-substituted purine analogues and other molecules to stimulate neurogenesis
US6906190B2 (en) * 2002-01-04 2005-06-14 Ribapharm Inc. Inhibitors for de novo-RNA polymerases and methods of identifying targets for same
US7132103B2 (en) * 2003-08-01 2006-11-07 Enhan Technology Holdings International Co., Ltd. Effects of sporoderm-broken germination activated ganoderma spores on treatment of spinal cord injury
US20080039247A1 (en) * 2006-08-02 2008-02-14 Sandra L. Uhler Footbag And A System Relating Thereto
KR102156871B1 (ko) 2020-01-13 2020-09-24 주식회사 제이에스티 비산 저감이 가능한 집진장치를 이용한 하이브리드 폴리우레아 복합방수공법

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3321369A (en) 1965-05-26 1967-05-23 Abbott Lab Method of enhancing learning rate and retention level in warm blooded animals
US3438486A (en) 1966-08-17 1969-04-15 David Pinkas Pick array
BE759011A (fr) 1969-11-17 1971-05-17 Wellcome Found Aminopurines
DE2554453A1 (de) 1974-12-18 1976-06-24 Experimentales Et Cliniques De Medikament zur glykaemieregulierung
US4221909A (en) 1978-09-15 1980-09-09 Sloan-Kettering Institute For Cancer Research P-Acetamidobenzoic acid salts of 9-(hydroxyalkyl) purines
US4340726A (en) 1980-03-14 1982-07-20 Newport Pharmaceuticals International, Inc. Esters
US4643992A (en) 1982-11-09 1987-02-17 Scripps Clinic And Research Foundation Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives
US5093318A (en) 1983-11-01 1992-03-03 Scripps Clinic And Research Foundation Immunostimulating guanosine derivatives and their pharmaceutical compositions
US4952693A (en) 1984-10-12 1990-08-28 Warner-Lambert Company Oxazolo-pyrimidine derivatives
US5495010A (en) 1987-04-17 1996-02-27 The United States Of America As Represented By The Department Of Health And Human Services Acid stable purine dideoxynucleosides
ATE140729T1 (de) 1988-04-19 1996-08-15 Pasteur Institut Verfahren zur gewinnung von schutzantigenen gegen bordetella-infektionen und toxische prozesse
IT1227389B (it) 1988-07-07 1991-04-08 Mini Ricerca Scient Tecnolog Dispersioni acquose di polimeri uretano-acrilici e loro impiego come vernici.
US5256677A (en) 1989-05-23 1993-10-26 Abbott Laboratories Retroviral protease inhibiting compounds
US5187162A (en) 1989-09-15 1993-02-16 Gensia Pharmaceuticals Methods of treating neurodegenerative conditions
US5026687A (en) 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
US5091432A (en) 1990-03-28 1992-02-25 Glasky Alvin J 9-substituted hypoxanthine bi-functional compounds and their neuroimmunological methods of use
US5237051A (en) 1990-12-06 1993-08-17 Vanderbilt University Purified enterotoxin receptor protein
US5447939A (en) 1994-07-25 1995-09-05 Glasky; Alvin J. Carbon monoxide dependent guanylyl cyclase modifiers and methods of use
US5801184A (en) 1994-07-25 1998-09-01 Glasky; Alvin J. Carbon monoxide dependent guanylyl cyclase modifiers and methods of use
US5795756A (en) 1995-12-11 1998-08-18 Johnson; Roger A. Method and compounds for the inhibition of adenylyl cyclase
US5948771A (en) 1996-01-31 1999-09-07 The Trustees Of Columbia University In The City Of New York Method for treating heart failure using tetrapyrroles and metallotetrapyrroles
US5801159A (en) 1996-02-23 1998-09-01 Galileo Laboratories, Inc. Method and composition for inhibiting cellular irreversible changes due to stress
WO1999056550A1 (en) 1998-05-04 1999-11-11 Neotherapeutics, Inc. Method for treating migraine in mammals
US6303617B1 (en) 1998-05-04 2001-10-16 Neotherapeutics, Inc. Serotonin-like 9-substituted hypoxanthine and methods of use
WO1999057119A1 (en) 1998-05-04 1999-11-11 Neotherapeutics, Inc. Novel dopamine-like 9-substituted hypoxanthine and methods of use

Also Published As

Publication number Publication date
EP1230242A1 (en) 2002-08-14
AU3637901A (en) 2001-05-30
EA200200572A1 (ru) 2003-02-27
US6288069B1 (en) 2001-09-11
BR0015574A (pt) 2005-04-12
WO2001036419A9 (en) 2002-08-08
NO20022325D0 (no) 2002-05-15
MXPA02004935A (es) 2005-09-08
JP2003517469A (ja) 2003-05-27
WO2001036419A1 (en) 2001-05-25
CA2387809A1 (en) 2001-05-25
KR20020050283A (ko) 2002-06-26
IL149561A0 (en) 2002-11-10

Similar Documents

Publication Publication Date Title
AU2007345952B2 (en) Positively charged water-soluble prodrugs of 1H-imidazo[4, 5-c]quinolin-4-amines and related compounds with very high skin penetration rates
EP3271370A1 (en) Nicotinic acid riboside or nicotinamide riboside compositions, reduced derivatives thereof, and the use thereof
WO2006063111A3 (en) Pharmaceutical formulations cytidine analogs and derivatives
DK1020179T3 (da) Peptidderivater eller farmaceutisk acceptable salte deraf, fremgangsmåde til fremstilling af de samme, anvendelse af derivaterne og farmaceutisk sammensætning
RU94042907A (ru) Производные имидазопиридина, способ их получения, фармацевтическая композиция и способ ее получения
BRPI0409427A (pt) composto, uso do mesmo, composição farmacêutica, método de tratamento de um humano sofrendo de uma doença hiperproliferativa, e, processo para a preparação de um composto ou de um sal, éster ou pró-droga farmaceuticamente aceitáveis do mesmo
CA2238875A1 (en) Tri-aryl ethane derivatives as pde iv inhibitors
JP2004532185A5 (no)
DE69834500D1 (de) Xanthinderivative zur behandlung von hirnischämie
DE69824313D1 (de) Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen
NO20022325L (no) Anvendelse av 9-substituerte hypoxantinderivater for å stimulere regenerering av nervevev
SG145570A1 (en) 4-æ7-halo-2-quino(xa-)linyloxy!phenoxy-propionic acid derivatives as antineoplastic agents
ES2053668T3 (es) Derivados de poliamina como agentes antineoplasicos.
KR970703152A (ko) 치료제 용도의 피리딜비스인산염(pyridylbisphosphonates for use as a therapeutical agent)
EE9800233A (et) Benso[c]kinolisiini derivaadid, nende valmistamine ja kasutamine 5a-reduktaasi inhibiitoritena
BR0016601A (pt) Composição farmacêutica para a prevenção ou tratamento da ejaculação precoce e/ou da hipersensibilidade da estimulação sexual
ES2118650T3 (es) Derivados de la quinolina-4-carbonilguanidina, procedimiento para la preparacion de los mismos y preparaciones farmaceuticas que contienen los compuestos.
CA2301590A1 (en) 2-aminopyridines as inhibitors of cyclooxygenase-2
FR2618435B1 (fr) Derives de benzimidazole, leur preparation et leur application en therapeutique
NO20016301L (no) Terapeutiske midler
AR008245A1 (es) Derivados de acido acetico, uso de los mismos en la fabricacion de un agente terapeutico y proceso para preparar dichos derivados
FI97883B (fi) Menetelmä lääkeaineena käyttökelpoisen glyserolijohdannaisen valmistamiseksi
MXPA04000485A (es) Uso de acidos aril o heteroaril hidroxamicos de sulfonilo y derivados de los mismos como inhibidores de agrecanasa.
ES2176258T3 (es) Uso de penciclovir en el tratamiento de la neuralgia post-herpeticas. a
DE69914563D1 (de) Azaindol derivate und ihre Verwendung als antithrombotische Wirkstoffe

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application